<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085080</url>
  </required_header>
  <id_info>
    <org_study_id>Chi-NELS</org_study_id>
    <nct_id>NCT05085080</nct_id>
  </id_info>
  <brief_title>Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS)</brief_title>
  <official_title>Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Neonatal Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO),&#xD;
      is an extracorporeal technique which provides respiratory and cardiac support to patients&#xD;
      with respiratory and/or heart failure. Neonates account for a significant proportion of&#xD;
      patients requiring ECLS support. While with unique pathophysiology among newborn infants,&#xD;
      neonatal ECLS treatment faces different challenges (such as specific indications,&#xD;
      anticoagulation, hemodynamic management, high incidences of complications, ect.) from those&#xD;
      of elder children or adults. Though neonatal ECMO has been used in developed countries since&#xD;
      1970s, the introduction of neonatal ECMO in China was not reported until 2010s. While on the&#xD;
      other hand, there has been a rapid increase of neonatal ECLS cases and centers in China in&#xD;
      the past decade with a huge variation of numbers of cases and quality among different&#xD;
      centers. Therefore, there is an urgent need to monitor the use and quality of neonatal ECLS&#xD;
      in China. The goal of the Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS) is&#xD;
      to maintain a registry of use of ECLS in active neonatal ECLS centers across China, to&#xD;
      support quality improvement of neonatal ELCS, clinical research and regulatory agencies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to establish a neonatal ECLS network of all active ECLS centers in China to&#xD;
      facilitate standardization of care and collaborative research. On the basis of the network,&#xD;
      this prospective comprehensive registry will enroll all neonates who receive ECLS support in&#xD;
      participating centers. The indications, managements, complications and outcomes of neonatal&#xD;
      ECLS in China will be described in detail, to monitor the development of neonatal ECLS in&#xD;
      China, to identify targets for quality improvement, to assist in reducing mortality and&#xD;
      morbidity of neonates requiring ECLS support, and to facilitate innovative clinical&#xD;
      researches.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>From admission to discharge or death, an average of 3 months</time_frame>
    <description>Mortality during NICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of successful weaning from ECLS</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants who were successfully weaning from ECLS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mechanical complications</measure>
    <time_frame>During ECLS, an average of 3 months</time_frame>
    <description>Complication related to the ECLS circuit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemorrhage</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Hemorrhage complication including bleeding at gastrointestinal tract, cannulation site, or surgical site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brain death</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Brain death is diagnosed according to the definition published on critical care medcine in 2011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of seizure</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Seizure was confirmed by EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diffuse ischemia of central nervous system (CNS)</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with diffuse ischemia of central nervous system (CNS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CNS infarction</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with CNS infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intraventricular hemorrhage</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with intraventricular hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal failure</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CPR required</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants required CPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiac arrhythmia</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with cardiac arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumothorax</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary hemorrhage</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with pulmonary hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemolysis</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants with hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of limb ischemia</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Proportion of infants limb ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Infection include pneumonia, sepsis, urinary tract infection, central nervous system infection etc..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of hospital stay</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>All costs during hospitallization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>From admission to discharge or dealth, an average of 3 months</time_frame>
    <description>Days of mechanical ventilation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Extracorporeal Life Support</condition>
  <condition>Neonate</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All neonate recieved ECLS support&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¤28 days of life&#xD;
&#xD;
          -  receive ECLS support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Cao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun Cao, Ph.D. M.D.</last_name>
    <phone>+8602164931160</phone>
    <email>yuncao@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siyuan Jiang, Ph.D. M.D.</last_name>
    <phone>+8602164931160</phone>
    <email>jane1350@163.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

